Venture Life Group PLC (VLG) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Venture Life Group PLC £0.39, price £0.68, upside -42.7%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Venture Life Group PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range £0.2350 – £0.9950 · fair‑value band £0.3315 – £0.4930 · the £0.6820 price screens above the £0.3910 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Venture Life Group in your weekly email
Every Wednesday you see whether Venture Life Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom.
Show more
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms related to rosacea; Bioscalin for the cosmetic treatment and prevention of hair loss, hair thinning, and baldness; and skincare solutions under the brand Lubatti. In addition, the company offers women's healthcare products, including BV treatment gel and pessaries; intimate daily wash and soothing cream; moisture gel and plus pessaries; and thrush cream under Balance Activ name. Further, it provides glucose management products, such as Lift Glucose shots and tablets for the immediate treatment of hypoglycaemia and preventing hypos; Glucogel for the treatment of hypoglycaemia. Additionally, the company offers ENT care products comprising Earol, for the removal of ear wax; EarolSwim, an invisible ear plugs for protecting the ears from water ingress; and Baby Earol, an ear spray for babies under the Earol and EarolSwim brands. It also provides oncology support products, such as Pomi-T for the management of prostate-specific antigen levels in prostate cancer; Gelclair, a muco-adhesive oral rinse for the treatment of Oral Mucositis; and Xonrid, a hyaluronic acid-based topical gel, for the prevention and treatment of radiation-induced dermatitis. The company operates in Germany, the Netherlands, France, Sweden, Denmark, Lithuania, rest of Europe, the United States, Canada, Brazil, Ireland, and internationally. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.
Stock analysis
Venture Life Group PLC (VLG) currently trades at £0.6820, while our model-based Fair Value estimate is £0.3910, implying the stock looks roughly 74.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of £2.31 per share, and 7 of the 15 models we run sit above the £0.6820 price.
Bear case: the Economic Profit group reads lowest at £0.1600, and 8 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: £0.3315 (bear) to £0.4930 (bull), the price of £0.6820 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Venture Life Group PLC reported revenue of 35.2M GBX in FY2025 versus 32.8M GBX in FY2021, a compound +1.8%/yr. Reported net income was 6.1M GBX in FY2025, compounding +26.4%/yr from FY2021.
Key figures
Market cap 95.5M GBX · P/S ratio 2.29 · EPS (TTM) £−0.0100 · Net margin 17.4% · Return on equity −2.4% · Return on assets (EBIT) 1.6% · Operating margin −16.0% · Revenue (TTM) £35.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 27% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −15% fair-value upside, at −43%, VLG screens richer than that median.
Fair Value models
Bear £0.3315Fair Value £0.3910Bull £0.4930
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Start year 2020 (pandemic). Over 10 years: +14.5% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−11.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 3%
2025 sits 711% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 249 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−43% · Bottom 25%
Profitability
Return on assets1% · Below median
Net margin (TTM)17% · Top 25%
Operating margin (TTM)−16% · Bottom 25%
Growth and dividend
Revenue growth333% · Top 25%
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B1.55× · Pricier than median
P/S (TTM)3.60× · Priciest 25%
EV/EBITDA21.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 8
PAST (return on equity)0· sector 27
HEALTH (low debt)87· sector 98
DIVIDEND (yield)0· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Venture Life Group PLC Fair Value". https://www.fairvalue-calculator.com/stock/VLG
Frequently asked questions
Is Venture Life Group PLC (VLG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of £0.3910 versus a price of £0.6820, about −43% upside (overvalued).
What is the fair value of VLG?
Our model-based fair value for Venture Life Group PLC is £0.3910 (as of Sep 23, 2026), built from audited fundamentals. The current price: £0.6820.
What is the quality score of VLG?
Venture Life Group PLC has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Venture Life Group PLC (VLG)?
Our model-based price target is the fair value of £0.3910 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario £0.3315, optimistic scenario £0.4930. It is a calculation from audited fundamentals, not an analyst target.
What is the Venture Life Group PLC stock forecast for 2026?
Our models put fair value at £0.3910, about −43% upside versus a price of £0.6820 (overvalued). Cautious scenario £0.3315, optimistic scenario £0.4930. The calculation is refreshed regularly with new filings.
What is the revenue of Venture Life Group PLC (VLG)?
Venture Life Group PLC reported trailing-twelve-month revenue of about £35.2M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Venture Life Group PLC (VLG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Venture Life Group PLC it is £0.3910 per share (as of Sep 23, 2026), against a price of £0.6820. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Venture Life Group PLC stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VLG trades above its calculated fair value: price £0.6820, fair value £0.3910, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VLG?
No. The price is what the market pays today (£0.6820); the fair value is what the company's own numbers justify (£0.3910). For Venture Life Group PLC the two are £0.2910 per share apart. That gap is exactly why we show both numbers side by side.
How much is Venture Life Group PLC worth?
The market values Venture Life Group PLC at about 95.5M GBX (market capitalisation, as of Sep 23, 2026). Per share that is £0.6820; our models calculate a fair value of £0.3910 per share.
What do the bullish and bearish scenarios say about VLG?
Our models span a range for Venture Life Group PLC: cautious scenario £0.3315, base £0.3910, optimistic £0.4930 per share (as of Sep 23, 2026, price £0.6820). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Venture Life Group PLC (VLG)?
Balance-sheet figures for Venture Life Group PLC (as of Sep 23, 2026): return on equity −2.4%, debt of 0.27 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is VLG from its 52-week high?
Venture Life Group PLC trades at £0.6820, about 4% below its 52-week high of £0.7100 and 27% above the low of £0.5350 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.3910 is for.
Which stocks are comparable to Venture Life Group PLC?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Venture Life Group PLC stock attractive at the current price?
The data as of Sep 23, 2026: price £0.6820, calculated fair value £0.3910 (−43%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VLG calculated?
We run Venture Life Group PLC through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.3910, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Venture Life Group PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Venture Life Group PLC (VLG)?
The closing price on Sep 24, 2026 was £0.6820. Our model-based fair value is £0.3910, about −43% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Venture Life Group PLC right now?
The price sits above even our optimistic bull case (£0.4930). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Venture Life Group PLC
How large is the market capitalisation of Venture Life Group PLC (VLG)?
The market capitalisation of Venture Life Group PLC is 95.5M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Venture Life Group PLC (VLG)?
The price-to-sales ratio of Venture Life Group PLC is 2.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Venture Life Group PLC (VLG)?
Earnings per share at Venture Life Group PLC are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Venture Life Group PLC (VLG)?
The net margin of Venture Life Group PLC is 17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Venture Life Group PLC (VLG)?
The return on equity (ROE) of Venture Life Group PLC is −2.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Venture Life Group PLC (VLG)?
On an EBIT basis the return on assets of Venture Life Group PLC is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Venture Life Group PLC (VLG)?
The operating margin of Venture Life Group PLC is −16.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Venture Life Group PLC (VLG)?
Revenue at Venture Life Group PLC is growing +333% versus a year earlier (3y avg −7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Venture Life Group PLC (VLG)?
Earnings per share at Venture Life Group PLC are growing +223% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Venture Life Group PLC (VLG) generate?
The free cash flow of Venture Life Group PLC is −309K GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Venture Life Group PLC (VLG) hold?
Venture Life Group PLC holds more cash than debt, 33.5M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Venture Life Group PLC in the live analysis
One click puts Venture Life Group PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
